Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study-Reference-Cited by-同舟云学术

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Published:2013-08 Issue:9893 Volume:382 Page:700-708
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Cahn Pedro,Pozniak Anton L,Mingrone Horacio,Shuldyakov Andrey,Brites Carlos,Andrade-Villanueva Jaime F,Richmond Gary,Buendia Carlos Beltran,Fourie Jan,Ramgopal Moti,Hagins Debbie,Felizarta Franco,Madruga Jose,Reuter Tania,Newman Tamara,Small Catherine B,Lombaard John,Grinsztejn Beatriz,Dorey David,Underwood Mark,Griffith Sandy,Min Sherene

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses;Lennox;J Acquir Immune Defic Syndr,2010

2. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks;Sax;Lancet,2012

3. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

4. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study;Molina;Lancet Infect Dis,2012

5. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial;Eron;Lancet Infect Dis,2011

Cited by 464 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Model‐Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed‐Dose Combination Approval in Children Living with HIV‐1;The Journal of Clinical Pharmacology;2024-09-05

2. Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations;International Journal of Antimicrobial Agents;2024-09

3. HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania;PLOS ONE;2024-08-14

4. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir;Viruses;2024-07-19

5. Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics;Clinical Pharmacology & Therapeutics;2024-07-16